Acute Myeloid Leukemia Archives - Cancer Therapy Advisor

Tandem Meetings 2022

Adding Eprenetapopt to Maintenance Azacitidine Promising After HCT in MDS/AML

By

May 10, 2022

Researchers sought to determine whether adding eprenetapopt to maintenance azacitidine after HCT would be effective in patients with AML or MDS.

Tandem Meetings 2022

Relapse Risk Lower With Double CBT Than With Matched Sibling or Unrelated Transplant

By

Sucharita Mistry, PhD

May 5, 2022

There was no significant difference in transplant-related mortality or overall survival.

Hematologic Cancers

Idasanutlin Does Not Improve OS in Relapsed/Refractory Acute Myeloid Leukemia

By

Sucharita Mistry, PhD

May 4, 2022

There was no survival improvement with idasanutlin in the overall population or among patients with wild-type TP53.

Hematologic Cancers

Ivosidenib + Azacitidine Ups Event-Free Survival in IDH1-Mutated AML

April 22, 2022

Ivosidenib plus azacitidine prolonged event-free and overall survival compared with azacitidine alone.

Hematologic Cancers

Idarubicin Hydrochloride Injection Recalled Due to Presence of Particulate in Vial

By

Brian Park, PharmD

April 4, 2022

Idarubicin Hydrochloride Injection is indicated in combination with other approved anti-leukemic drugs for the treatment of acute myeloid leukemia in adults.

NCCN 2022

AML Incidence and Deaths Increasing Worldwide

By

John Schieszer

April 2, 2022

Although mortality-to-incidence indices are improving globally, the increasing burden of AML is “concerning,” according to researchers.

Hematologic Cancers

Dioxin Exposure From Agent Orange Linked to AML and MDS

By

Vicki Moore, PhD

April 1, 2022

Researchers sought to examine relationships between leukemogenesis, Agent Orange, and a dioxin commonly found as a contaminant of Agent Orange.

Hematologic Cancers

Survival Inferior in Black Patients With Acute Myeloid Leukemia

March 28, 2022

Most disparities in acute myeloid leukemia death were accounted for by census tract measures.

Hematologic Cancers

Gilteritinib Provides Long-Term Benefit in Rel/Ref FLT3-Mutated Acute Myeloid Leukemia

By

Sucharita Mistry, PhD

February 4, 2022

The 2-year overall survival rate was 20.6% in the gilteritinib arm and 14.2% in the salvage chemotherapy arm.

Hematologic Cancers

Shifts Seen in Treatment Patterns for Older Patients With Acute Myeloid Leukemia

By

Vicki Moore, PhD

January 20, 2022

A new study shows a changing landscape of frontline treatment for older patients with acute myeloid leukemia and opportunities to increase treatment options.